Alto Neuroscience Inc. (NYSE: ANRO) announced it has completed patient enrollment in a phase 2 proof-of-concept clinical trial evaluating ALTO-101 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE